SPRO insider transaction filings
Spero Therapeutics, Inc. — 49 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-06. Screen SPRO transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 8 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 16.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Deshpande Milind — Director | 1 | — | — | 2 |
| Jackson Scott Thomas — Director | 1 | — | — | 2 |
| Pottage John C Jr — Director | 1 | — | — | 2 |
| Smith Cynthia — Director | 1 | — | — | 2 |
| THOMAS FRANK E — Director | 1 | — | — | 2 |
| Tregoning Kathleen — Director | 1 | — | — | 2 |
| VINK PATRICK V.J.J. — Director | 1 | — | — | 2 |
| Zack Debra — Chief Medical Officer | 1 | — | — | 2 |
Recent Form 4 filings — Spero Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-06 | 4 | Zack Debra — Chief Medical Officer | Grant/award (A): 162,311 @ $0 · Grant/award (A): 324,675 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Tregoning Kathleen — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Smith Cynthia — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Jackson Scott Thomas — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | VINK PATRICK V.J.J. — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Deshpande Milind — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Pottage John C Jr — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | THOMAS FRANK E — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | Rajavelu Esther — See Remarks | Sale (S): 25,240 @ $2.51 | EDGAR |
| 2026-02-09 | 4 | Rajavelu Esther — See Remarks | Sale (S): 37,101 @ $2.36 · Sale (S): 50,816 @ $2.36 | EDGAR |
| 2026-02-09 | 4 | Keutzer Timothy — Chief Operating Officer | Sale (S): 18,652 @ $2.36 | EDGAR |
| 2026-02-05 | 4 | Keutzer Timothy — Chief Operating Officer | Grant/award (A): 68,000 @ $0 · Sale (S): 18,891 @ $2.20 · Sale (S): 24,224 @ $2.14 · Sale (S): 3,471 @ $2.24 · Grant/award (A): 137,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Rajavelu Esther — See Remarks | Grant/award (A): 249,000 @ $0 · Sale (S): 18,442 @ $2.20 · Grant/award (A): 498,000 (derivative) @ $0 | EDGAR |
| 2025-11-12 | 4 | Rajavelu Esther — See Remarks | Sale (S): 40,270 @ $2.37 | EDGAR |
| 2025-09-03 | 4 | Mahadevia Ankit — Director | Sale (S): 6,572 @ $1.97 | EDGAR |
| 2025-09-03 | 4 | Keutzer Timothy — Chief Operating Officer | Sale (S): 1,695 @ $1.97 | EDGAR |
| 2025-06-16 | 4 | Tregoning Kathleen — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-06-16 | 4 | Mahadevia Ankit — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-06-16 | 4 | Smith Cynthia — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-06-16 | 4 | Jackson Scott Thomas — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-06-16 | 4 | VINK PATRICK V.J.J. — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-06-16 | 4 | Deshpande Milind — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-06-16 | 4 | Pottage John C Jr — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-06-16 | 4 | THOMAS FRANK E — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-05-06 | 4 | Rajavelu Esther — See Remarks | Grant/award (A): 185,000 @ $0 | EDGAR |
| 2025-02-05 | 4 | Keutzer Timothy — Chief Operating Officer | Grant/award (A): 266,139 @ $0 · Sale (S): 3,974 @ $0.78 · Sale (S): 27,643 @ $0.78 · Sale (S): 24,920 @ $0.78 | EDGAR |
| 2025-02-05 | 4 | Rajavelu Esther — CFO & CBO | Grant/award (A): 266,139 @ $0 · Grant/award (A): 100,000 @ $0 · Sale (S): 20,689 @ $0.78 | EDGAR |
| 2025-02-05 | 4 | Shukla Sath — CEO & President | Grant/award (A): 751,407 @ $0 · Sale (S): 6,139 @ $0.78 · Sale (S): 42,786 @ $0.78 · Sale (S): 106,408 @ $0.78 | EDGAR |
| 2025-02-05 | 4 | Mahadevia Ankit — Director | Sale (S): 13,959 @ $0.78 · Sale (S): 55,260 @ $0.78 | EDGAR |
| 2024-11-12 | 4 | Rajavelu Esther — CFO & CBO | Sale (S): 23,351 @ $1.31 · Sale (S): 17,245 @ $1.30 | EDGAR |
| 2024-08-29 | 4 | Mahadevia Ankit — Director | Sale (S): 5,912 @ $1.35 | EDGAR |
| 2024-08-29 | 4 | Keutzer Timothy — Chief Operating Officer | Sale (S): 2,213 @ $1.35 | EDGAR |
| 2024-08-29 | 4 | Shukla Sath — CEO & President | Sale (S): 2,757 @ $1.35 | EDGAR |
| 2024-08-06 | 4 | Shukla Sath — CEO and President | Sale (S): 14,800 @ $1.32 · Sale (S): 17,641 @ $1.31 | EDGAR |
| 2024-05-30 | 4 | Mahadevia Ankit — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2024-05-30 | 4 | Tregoning Kathleen — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2024-05-30 | 4 | Smith Cynthia — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2024-05-30 | 4 | Jackson Scott Thomas — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2024-05-30 | 4 | VINK PATRICK V.J.J. — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2024-05-30 | 4 | Deshpande Milind — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2024-05-30 | 4 | Pottage John C Jr — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2024-05-30 | 4 | THOMAS FRANK E — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2024-02-05 | 4 | Keutzer Timothy — Chief Operating Officer | Grant/award (A): 239,731 @ $0 · Sale (S): 30,971 @ $1.36 | EDGAR |
| 2024-02-05 | 4 | Mahadevia Ankit — Director | Sale (S): 63,795 @ $1.37 | EDGAR |
| 2024-02-05 | 4 | HAMED KAMAL — Chief Medical Officer | Grant/award (A): 239,731 @ $0 · Sale (S): 28,075 @ $1.37 | EDGAR |
| 2024-02-05 | 4 | Rajavelu Esther — See Remarks | Grant/award (A): 119,866 @ $0 | EDGAR |
| 2024-02-05 | 4 | Shukla Sath — CEO and President, Director | Grant/award (A): 679,501 @ $0 · Sale (S): 30,901 @ $1.37 · Sale (S): 45,093 @ $1.45 | EDGAR |
| 2024-02-05 | 4 | JOSEPH TAMARA L — Chief Legal Officer | Grant/award (A): 239,731 @ $0 · Sale (S): 30,906 @ $1.37 | EDGAR |
| 2024-01-04 | 4 | Tregoning Kathleen — Director | Grant/award (A): 35,604 (derivative) @ $1.12 | EDGAR |
Recent 8-K events — Spero Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-25 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events | EDGAR |
| 2025-12-19 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SPRO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →